Facebook
Twitter
Telegram
Report an ErrorInhibikase Therapeutics Balance Sheet 2011-2024 | IKT
Annual Balance Sheet Inhibikase Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-8.64 M | -6.84 M | - | -13.9 K | 355 K | -146 K | - | - | - | - | - | - | - |
Long Term Debt |
382 K | 205 K | - | - | 275 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
150 K | 146 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 275 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
3.44 M | 3.7 M | 4.05 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.53 M | 3.9 M | 4.05 M | 5 K | 4.53 M | 3.62 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 2.33 K | 1.43 M | 262 K | - | - | - | - | - | - | - |
Retained Earnings |
-66.9 M | -47.9 M | -29.8 M | - | -12.2 M | -6.46 M | - | - | - | - | - | - | - |
Total Assets |
14.5 M | 24.9 M | 42.5 M | 14.8 K | 38.3 K | 2.85 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
9.17 M | 7.19 M | 40.8 M | 14 M | - | - | - | - | - | - | - | - | - |
Book Value |
11 M | 21 M | 38.4 M | 9.78 K | -4.49 M | -778 K | - | - | - | - | - | - | - |
Total Shareholders Equity |
11 M | 21 M | 38.4 M | 9.78 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Inhibikase Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
58.3 K | - | 121 K | 150 K | 178 K | - | 232 K | - | - | 249 K | 249 K | 249 K | 1.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.29 M | 3.53 M | 2.86 M | 2.88 M | 2.84 M | 3.9 M | 3.45 M | 4.49 M | 4.38 M | 4.05 M | 2.71 M | 2.16 M | 3.84 M | 5 M | 5 M | 5 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 143 K | 1.25 M | 2.33 M | 2.33 M | 2.33 M | 2.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-71.6 M | -66.9 M | -62.7 M | -58.1 M | -52.3 M | -47.9 M | -43.6 M | -39.1 M | -34.5 M | -29.8 M | -24.8 M | -20.3 M | -17.7 M | 15 M | -15 M | -15 M | -15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
11.1 M | 14.5 M | 17.9 M | 22.3 M | 28.2 M | 24.9 M | 28.6 M | 34 M | 38.4 M | 42.5 M | 45.9 M | 49.2 M | 11.9 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2.35 M | 9.17 M | 14.9 M | 1.91 M | 3.96 M | 7.19 M | 5.78 M | 32.2 M | 36.6 M | 40.8 M | 44.8 M | 46.8 M | 9.61 M | 14 M | 14 M | 14 M | 14 M | 18.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6.78 M | 11 M | 15 M | 19.5 M | 25.3 M | 21 M | 25.1 M | 29.5 M | 34 M | 38.4 M | 43.2 M | 47.1 M | 8.04 M | 9.78 M | 9.78 M | 9.78 M | 9.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.78 M | 11 M | 15 M | 19.5 M | 25.3 M | 21 M | 25.1 M | 29.5 M | 34 M | 38.4 M | 43.2 M | 47.1 M | 8.04 M | 9.78 M | 9.78 M | 9.78 M | 9.78 M | -4.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency